Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $4.45 billion. The enterprise value is $5.13 billion.
| Market Cap | 4.45B |
| Enterprise Value | 5.13B |
Important Dates
The next confirmed earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 50.79 million shares outstanding. The number of shares has increased by 0.44% in one year.
| Shares Outstanding | 50.79M |
| Shares Change (YoY) | +0.44% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.76% |
| Owned by Institutions (%) | 101.57% |
| Float | 50.37M |
Valuation Ratios
The trailing PE ratio is 35.63 and the forward PE ratio is 20.85. Haemonetics's PEG ratio is 1.63.
| PE Ratio | 35.63 |
| Forward PE | 20.85 |
| PS Ratio | 3.50 |
| Forward PS | 3.25 |
| PB Ratio | 4.72 |
| P/FCF Ratio | 35.92 |
| PEG Ratio | 1.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.45, with an EV/FCF ratio of 41.38.
| EV / Earnings | 40.52 |
| EV / Sales | 4.04 |
| EV / EBITDA | 19.45 |
| EV / EBIT | 30.13 |
| EV / FCF | 41.38 |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 0.92.
| Current Ratio | 2.92 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 3.30 |
| Debt / FCF | 7.03 |
| Interest Coverage | 18.67 |
Financial Efficiency
Return on equity (ROE) is 14.40% and return on invested capital (ROIC) is 7.37%.
| Return on Equity (ROE) | 14.40% |
| Return on Assets (ROA) | 6.20% |
| Return on Capital (ROIC) | 7.37% |
| Revenue Per Employee | $418,649 |
| Profits Per Employee | $41,719 |
| Employee Count | 3,034 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.14 |
Taxes
In the past 12 months, Haemonetics has paid $34.50 million in taxes.
| Income Tax | 34.50M |
| Effective Tax Rate | 21.42% |
Stock Price Statistics
The stock price has increased by +5.44% in the last 52 weeks. The beta is 0.36, so Haemonetics's price volatility has been lower than the market average.
| Beta (1Y) | 0.36 |
| 52-Week Price Change | +5.44% |
| 50-Day Moving Average | 79.73 |
| 200-Day Moving Average | 84.84 |
| Relative Strength Index (RSI) | 63.90 |
| Average Volume (30 Days) | 484,795 |
Short Selling Information
The latest short interest is 2.04 million, so 4.01% of the outstanding shares have been sold short.
| Short Interest | 2.04M |
| Short Previous Month | 1.96M |
| Short % of Shares Out | 4.01% |
| Short % of Float | 4.04% |
| Short Ratio (days to cover) | 4.36 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.27 billion and earned $126.57 million in profits. Earnings per share was $2.46.
| Revenue | 1.27B |
| Gross Profit | 671.89M |
| Operating Income | 170.20M |
| Pretax Income | 161.08M |
| Net Income | 126.57M |
| EBITDA | 263.63M |
| EBIT | 170.20M |
| Earnings Per Share (EPS) | $2.46 |
Balance Sheet
The company has $193.98 million in cash and $870.59 million in debt, giving a net cash position of -$676.61 million or -$13.32 per share.
| Cash & Cash Equivalents | 193.98M |
| Total Debt | 870.59M |
| Net Cash | -676.61M |
| Net Cash Per Share | -$13.32 |
| Equity / Book Value | 943.32M |
| Book Value Per Share | 18.57 |
| Working Capital | 503.23M |
Cash Flow
In the last 12 months, operating cash flow was $197.28 million and capital expenditures -$73.36 million, giving a free cash flow of $123.92 million.
| Operating Cash Flow | 197.28M |
| Capital Expenditures | -73.36M |
| Free Cash Flow | 123.92M |
| FCF Per Share | $2.44 |
Margins
Gross margin is 52.90%, with operating and profit margins of 13.40% and 9.97%.
| Gross Margin | 52.90% |
| Operating Margin | 13.40% |
| Pretax Margin | 12.68% |
| Profit Margin | 9.97% |
| EBITDA Margin | 20.75% |
| EBIT Margin | 13.40% |
| FCF Margin | 9.76% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.44% |
| Shareholder Yield | -0.44% |
| Earnings Yield | 2.84% |
| FCF Yield | 2.78% |
Analyst Forecast
The average price target for Haemonetics is $102.50, which is 16.93% higher than the current price. The consensus rating is "Buy".
| Price Target | $102.50 |
| Price Target Difference | 16.93% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 8.89% |
| EPS Growth Forecast (5Y) | 26.17% |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 3.45 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.45 |
| Piotroski F-Score | 6 |